AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03057106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: MEDI4736
Study NCT03057106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab
Study NCT03057106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: Pemetrexed, cisplatin, carboplatin or gemcitibine
Study NCT02298829 — intervention group
Intervention type: DRUG
Intervention: Subjects Previously Treated with AA4500
Description: no treatment to be administered - observational only
Study NCT00283075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Macrobead placement in abdominal cavity
Description: 8 macrobeads per kg
Study NCT03603821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CLINICAL ASSESMENT
Description: IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
Study NCT03617991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
Study NCT03478111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB008
Description: the study drug
Study NCT03478111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: basic therapy drug
Study NCT03478111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: basic therapy drug
Study NCT03478111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: active comparator
Study NCT02263898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raf kinase inhibitor LGX818
Description: Given PO
Study NCT02263898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Given PO
Study NCT02263898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03778619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
Study NCT03778619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Study NCT03778619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Study NCT03778619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG4101(allogeneic Natural Killer cell)
Description: administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
Study NCT03778619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 1 x 10\^6 IU/m2, together with MG4101
Study NCT03516682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
Study NCT00563186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Admission to a novel hospital ward
Description: Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Description: Carotid endarterectomy (CEA) will be performed on the patients
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting (CAS)
Description: Carotid Stenting (CAS) will be performed on these patients.
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurocognitive functions
Description: Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levels of biomarkers
Description: Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection of peri-operative embolization
Description: A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
Study NCT01337128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Validation results
Description: On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
Study NCT03424707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW340(pelubiprofen/eperisone)
Description: DW340
Study NCT03424707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubi(pelubiprofen)
Description: pelubiprofen
Study NCT03424707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT02821871 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Study NCT02821871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high fat diet
Study NCT01530984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
Study NCT01530984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
Study NCT00896207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose
Study NCT03920319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion 150 mg sustained release
Study NCT03920319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04570319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bths-08
Description: A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
Study NCT04570319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
Study NCT00882609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Description: Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
Study NCT00882609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Description: Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
Study NCT03512600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 0
Description: Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
Study NCT03512600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.
Study NCT03512600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.
Study NCT03512600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.
Study NCT00879645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
Study NCT00879645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
Study NCT00470886 — intervention group
Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
Study NCT00540852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffuse Optical Spectroscopy Imaging
Description: Diffuse Optical Spectroscopy Imaging
Study NCT04756908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
Study NCT04756908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
Study NCT01262989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Study NCT01262989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: tamsulosin 0,4 mg (Boehringer Ingelheim)
Study NCT03314922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
Study NCT02290678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based Programming
Study NCT04380519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH-104 80 mg
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT04380519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64 mg
Description: solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
Study NCT04380519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Study NCT04349800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900
Description: Active
Study NCT04349800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to KVD900
Description: Placebo
Study NCT02127957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
Study NCT00505401 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: recombinant HIV-1 Tat protein
Study NCT00441064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Study NCT02364635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosabutate
Description: Single dose at each dose levet
Study NCT02364635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: icosabutate
Description: Single dose at each dose levet
Study NCT00280384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2014 (Botulinum toxin type B)
Description: A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
Study NCT00280384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2014 (Botulinum toxin type B) Placebo
Description: A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
Study NCT04306861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
Study NCT01519869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
Study NCT03427580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MERIT
Description: Metacognitive Reflection and Insight Therapy
Study NCT02739971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low AGEs diet
Description: Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
Study NCT02739971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care dietary guidance for Type 2 diabetes
Description: Oral and written instructions for standard of care dietary guidance for type 2 diabetes
Study NCT02739971 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care dietary guidance for Type 2 diabetes
Description: Oral and written instructions for standard of care dietary guidance for type 2 diabetes
Study NCT01731418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, \& Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
Study NCT01731418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills
Study NCT04202172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction
Description: The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography
Study NCT04202172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction
Description: The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography
Study NCT03710083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3)
Description: Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
Study NCT03198325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop of ART
Description: Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
Study NCT01043913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guarana extract
Description: Guarana extract 50mg q12 hours for 21 days
Study NCT01043913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guarana extract
Description: Guarana extract 50mg q12 hours for 21 days
Study NCT02283762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
Study NCT00879645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
Study NCT02283762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham-titration
Study NCT02861274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker
Study NCT03565419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
Study NCT01438736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)
Description: Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
Study NCT01438736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68 mg subdermal implant
Description: Etonogestrel 68 mg subdermal implant for 6 months
Study NCT03969121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
Study NCT02049606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAYLA tablet
Description: 1 Tablet twice a day
Study NCT02049606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CENATONE tablet
Description: 2 Tablets once a day
Study NCT04049149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biogenetic explanation and endocrinologist intensive managment
Description: * JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires
Study NCT03969121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
Study NCT00573573 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
Study NCT04049149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care management
Description: * JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires